罗沙司他在慢性肾脏病患者肾性贫血治疗中的效果评价

Evaluation of the Effect of Roxadustat in the Treatment of Renal Anemia in Patients with Chronic Kidney Disease

目的:研究罗沙司他在慢性肾脏病患者肾性贫血治疗中的效果。方法:回顾性分析在2019年4月-2020年4月笔者所在医院收治的108例慢性肾脏病伴肾性贫血患者的资料,按治疗方式的不同将其分为常规组(54例,给予重组人促红素治疗)和研究组(54例,给予罗沙司他治疗)。比较两组的治疗前、治疗3个月后的铁代谢指标[血清铁蛋白(SF)、转铁蛋白(TRF)、转铁蛋白饱和度(TSAT)、铁调素(Hepc)]及贫血指标[红细胞计数(RBC)、血红蛋白(Hb)、血细胞比容(Hct)],并对比两组治疗后的不良反应发生率(心力衰竭、恶心、头痛、腹泻)。结果:治疗前,两组的铁代谢指标、贫血指标比较差异无统计学意义(P>0.05), 治疗后,研究组的Hepc水平低于常规组,而SF、TRF、TSAT水平则高于常规组(P<0.05), 且研究组的RBC、Hb、Hct水平均高于常规组(P<0.05)。研究组的不良反应发生率为5.56%,明显低于常规组的18.52%(P<0.05)。结论:采用罗沙司他为慢性肾脏病患者治疗肾性贫血,能明显改善患者的铁代谢指标、贫血指标,促进病情恢复,而且药物不良反应小,安全性好。

Objective:To study the effect of Roxadustat in the treatment of renal anemia in patients with chronic kidney disease.Method:The data of 108 patients with chronic kidney disease and renal anemia treated in our hospital from April 2019 to April 2020 were retrospectively analyzed.According to different treatment methods,they were divided into the conventional group(54 cases,given Recombinant Human Erythropoietin treatment)and the study group(54 cases,given Roxadustat treatment),with 54 cases in each group.The indexes of iron metabolism[serum ferritin(SF),transferrin(TRF),transferrin saturation(TSAT),hepcidin(HEPC)]and anemia indexes[red blood cell count(RBC),hemoglobin(HB),hematocrit(HCT)]were compared between the two groups before and 3 months after treatment,and the incidence of adverse reactions(heart failure,nausea,headache,diarrhea)between the two groups after treatment were compared.Result:Before treatment,there was no significant difference in iron metabolism index and anemia index between the two groups(P>0.05).After treatment,the level of HEPC in the study group was lower than that in the conventional group,while the levels of SF,TRF and TSAT in the study group were higher than those in the conventional group(P<0.05);and the levels of RBC,Hb and HCT in the study group were higher than those in the conventional group(P<0.05).The incidence of adverse reactions in the study group was 5.56%,which was significantly lower than 18.52%in the conventional group(P<0.05).Conclusion:For patients with chronic kidney disease,Roxadustat can significantly improve the iron metabolism index and anemia index,promote the recovery of the disease,and the adverse drug reactions are small and the safety is good.